Overview

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

Status:
Completed
Trial end date:
2019-03-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc
Insulin, Long-Acting
Metformin
Sodium-Glucose Transporter 2 Inhibitors